VII - Rare Tumors

Moderator(s)

• 

  Cathy Eng, MD, FACP, FASCO

  Vanderbilt-Ingram Cancer Center, MD Anderson Cancer Center
  MD Anderson Cancer Center

Presentations:

• 9:00 AM – 9:05 AM CDT

  Introduction and Pre-Session Audience Survey
  

  Moderator: Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center, MD Anderson Cancer Center
• 9:05 AM – 9:25 AM CDT

  Novel Agents and Approaches in Gastrointestinal Stromal Tumors (GIST)
  

  Speaker: George D. Demetri, MD, FACP, FASCO, FAACR – Dana-Farber Cancer Institute
• 9:25 AM – 9:45 AM CDT

  Management of Appendiceal Cancers
  

  Speaker: Michael J. Overman, MD – MD Anderson Cancer Center, The University of Texas
• 9:45 AM – 9:53 AM CDT

  Debate: Optimal Second-Line Therapy in Pancreatic Neuroendocrine Tumors (pNET): Capecitabine + Temozolomide (CAPTEM) vs. Peptide Receptor Radionuclide Therapy (PRRT). - Capecitabine + Temozolomide (CAPTEM)
  

  Debate Speaker: Jennifer R. Eads, MD – University of Pennsylvania, Abramson Cancer Center
• 9:53 AM – 10:01 AM CDT

  Debate: Optimal Second-Line Therapy in Pancreatic Neuroendocrine Tumors (pNET): Capecitabine + Temozolomide (CAPTEM) vs. Peptide Receptor Radionuclide Therapy (PRRT). - Peptide Receptor Radionuclide Therapy (PRRT)
  

  Debate Speaker: Jennifer A. Chan, MD, MPH – Dana-Farber Cancer Institute
• 10:01 AM – 10:05 AM CDT

  Debate Discussion
  

  Moderator: Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center, MD Anderson Cancer Center

  Panelist: Jennifer R. Eads, MD – University of Pennsylvania, Abramson Cancer Center

  Panelist: Jennifer A. Chan, MD, MPH – Dana-Farber Cancer Institute
• 10:05 AM – 10:50 AM CDT

  Q&A; Post-Session Audience Survey
  

  Moderator: Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center, MD Anderson Cancer Center

  Panelist: Jennifer R. Eads, MD – University of Pennsylvania, Abramson Cancer Center

  Panelist: Jennifer A. Chan, MD, MPH – Dana-Farber Cancer Institute

  Panelist: George D. Demetri, MD, FACP, FASCO, FAACR – Dana-Farber Cancer Institute

  Panelist: Michael J. Overman, MD – MD Anderson Cancer Center, The University of Texas

  Panelist: David H. Ilson, MD, PhD – Weill Cornell Medical College, Memorial Hospital, Memorial Sloan Kettering Cancer Center